Dengue Vaccine Market By Vaccine Type(Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, Other Vaccine Type), By End-User (Hospitals, Government Institutes, Other), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032

Report Overview

The Global Dengue Vaccine Market size is expected to be worth around USD 1,367.7 Mn by 2032 from USD 457 Mn in 2022, growing at a CAGR of 11.9% during the forecast period from 2023 to 2032.

Request Covid - 19 Impact

A wide range of immunization options against the dangerous dengue fever is what the market for dengue vaccines, encompassing the global market landscape, seeks to provide. These vaccines are ingeniously designed to induce an immune response in the human body, thereby enhancing the body's defense against the pernicious virus. With safety, efficacy, and global accessibility as its top priorities, the market strives to meet the urgent requirements of individuals worldwide.

With the advent of a previously unheard-of vaccine known as Dengvaxia, which was effectively approved by the esteemed FDA in 2019, the global dengue vaccine market experienced a significant breakthrough. This revolutionary vaccine has reduced the incidence of dengue fever by an astounding 60 percent among the immunized population.

In recent years, the dengue vaccine market has witnessed an increase in investments, as pharmaceutical giants such as Sanofi and Takeda have aggressively pursued vaccine research and development. Moreover, these industry titans have worked diligently to incorporate their vaccines into existing public health initiatives designed to combat dengue fever in countries where it is endemic.

In the coming years, eminent industry analysts anticipate a meteoric growth trajectory for the global dengue vaccine market. This favorable ascent will be propelled by the advent of novel vaccines and the increased acceptability and adoption of existing vaccines. The lion's share of this growth is anticipated to emanate from emerging markets, which will be predominantly concentrated in Asia and Latin America.

As the primary driver of the dengue vaccine market, the pharmaceutical industry, bolstered by Sanofi and Takeda, invests lavishly in the development of innovative vaccines that will ultimately save lives and combat the dengue threat.

Naturally, as with any innovative medical development, ethical dilemmas arise regarding the development and implementation of dengue vaccines. Accessibility, affordability, and security are at the vanguard of these ethical complexities. In this dynamic environment, it is of the utmost importance that all stakeholders collaborate harmoniously and address these issues with discretion to ensure responsible progress.

To continue its ascent and achieve long-term success, the global dengue vaccine market must prioritize openness, clarity, and responsibility. This requires an unambiguous commitment from all stakeholders to provide clear and concise information regarding the development, regulation, and distribution of vaccines.

The global dengue vaccine market offers a wide range of commercial opportunities, encompassing the development of novel vaccines, the seamless integration of existing vaccines into public health programs, and the establishment of innovative distribution channels and marketing strategies. This expanding market presents abundant opportunities for pharmaceutical giants, healthcare providers, and a variety of other stakeholders.

Driving factors

Rising Global Demand

The global dengue vaccine market is expanding, and the increasing prevalence of dengue fever around the world is the primary driver of this growth. Dengue fever is an ailment transmitted by mosquitoes that affects millions of people annually, primarily in tropical and subtropical regions. This disease's high prevalence has prompted increased awareness and prevention efforts, as well as advances in vaccine development.

Changing Legislation

Governments in endemic regions have instituted immunization programs to reduce the number of cases in response to the severity of this disease. These initiatives have contributed to the growth of the market for dengue vaccines, making it one of the most promising sectors of the global pharmaceutical industry.

Strategic Disruptors

Nevertheless, the regulatory landscape is constantly evolving, and any changes to regulations could have a substantial impact on the market. Companies will need to monitor prospective changes and adapt their strategies accordingly.

Emerging Trends

Despite the promising growth of the market for dengue vaccines, there are a number of potential factors that could have an impact on the competitive landscape. The emergence of new vaccine technologies or alternative treatment methods, for instance, could threaten the market dominance of established actors.

Growing Awareness

Finally, it is essential to consider any emerging trends or changes in consumer behavior that may have an impact on the market for dengue vaccine. As more people become aware of the dangers associated with dengue fever, there may be a shift toward preventative measures such as vaccination, which could fuel the market's growth.

Restraining Factors

Concerns Regarding the Global Dengue Vaccine Market's Security

Vaccines are a tool used in the medical field to stop the occurrence and transmission of disease. Vaccines against a variety of diseases, including dengue fever, have been developed. Dengue fever is a disease transmitted by mosquitoes that is prevalent in many tropical and subtropical areas. An estimated 400 million cases of dengue fever are reported each year, with a significant number leading to hospitalization or death.

Difficulties with Dengue Immunization

Concerns regarding the safety and efficacy of vaccines are one of the most significant restraints on the global dengue vaccine market. To ensure that they are willing to be immunized, it is essential for individuals to have faith in vaccines. However, there have been instances of vaccines causing adverse effects, leading to concerns regarding their safety. Given the potential severity of dengue fever, any adverse effects of the vaccine would harm the market. Vaccine providers must therefore ensure that they conduct exhaustive testing and monitoring of the vaccine.

Accessibility Restraints Dengue Vaccine Market

The complexity of immunization strategies required to immunize against dengue fever is an additional limiting factor. In contrast to other diseases for which a single vaccination is sufficient, dengue fever requires multiple doses to be effective. Additionally, the vaccine should not be administered to individuals who have never been afflicted with one of the strains of the dengue virus. As a result, the vaccine must target previously infected individuals, which may necessitate screening and testing.

Dengue Vaccine vs. Vector Control Measures

In addition to the complexity of immunization strategies, restricted access is another factor restraining the global dengue vaccine market. Dengue fever is prevalent in many tropical and subtropical regions where the population may have limited access to vaccines. In such areas, the healthcare infrastructure may be underdeveloped, making the provision of vaccines difficult. In addition, vaccine providers may encounter economic obstacles when supplying vaccines to highly prevalent disease regions. This lack of access to vaccines can substantially hinder market expansion.

Costs and Advantages of Dengue Vaccines

Effective vector control measures, such as the use of mosquito nets, insecticides, and educational campaigns, have reduced the prevalence of dengue fever. As the market for dengue vaccines expands, however, it may encounter competition from these control measures. Because vector control measures are cost-effective and simple to implement, individuals may choose them over the vaccine. Consequently, vaccine providers must ensure that the vaccine is priced competitively and offers additional advantages in comparison to control measures.

Vaccine Type Analysis

Dengue fever, a mosquito-borne viral disease that has affected millions of people worldwide, primarily in underdeveloped nations, is currently spreading throughout the world. Given this, a vaccine to prevent or control this disease's spread is a high goal. The Live Attenuated Vaccines Segment has led the global dengue vaccine market's growth.

The Live Attenuated Vaccines Segment—which includes Dengvaxia—leads the global dengue vaccine market. The live virus induces an immune response and disease immunity in this vaccine. The vaccine protects against all four dengue virus variants.

Economic growth in emerging markets is one driver driving Live Attenuated Vaccines Segment adoption. As these countries expand, healthcare, including vaccines, the need has increased. In addition, these economies are investing in healthcare infrastructure and extending access to services, making it possible for more people to get vaccinated.

The consumer trend and behavior toward this form of vaccine is another reason driving the adoption of the Live Attenuated Vaccines Segment. Vaccines protect individuals and the community, and awareness has grown in recent years. People are more ready to get vaccinated and invest in their health, making the Live Attenuated Vaccines Segment popular.

This growth can be attributed to rising vaccine demand, economic growth in emerging economies, vaccine importance, and vaccine research and development advancements.

End-User Analysis

In addition to vaccine type, the end-user segment of the global dengue vaccine market is crucial. Hospitals lead the market.

The Hospitals Segment, which includes private and public hospitals, dominates the global dengue vaccine market. This can be attributed to the fact that hospitals provide healthcare services, including vaccines, over the world.

Like the Live Attenuated Vaccines Segment, rising economies are driving Hospital Segment adoption. More people are seeking high-quality healthcare services, including immunizations, as their incomes rise. Hospital services have increased, making them more accessible.

Hospitals are becoming more popular for healthcare services including immunizations. Greater awareness of the importance of preventative care and a desire for better-quality healthcare services are driving the trend toward seeking out healthcare services from hospitals.

This growth can be attributed to economic growth in emerging economies, the trend toward seeking healthcare services in hospitals, and advancements in hospital infrastructure and technology.

Key Market Segments

By Product

• CYD-TDV (Dengvaxia)

By Vaccine Type

• Live Attenuated Vaccines
• Chimeric Live Attenuated Vaccines
• Other Vaccine Type

By End-User

• Hospitals
• Government Institutes
• Specialty Clinics
• Other End-Users

Growth Opportunity

Targeting High-Risk Areas Expanding Distribution and Access

This growth opportunity entails improving dengue vaccine market availability and accessibility in dengue-prone regions like Southeast Asia, Latin America, and the Caribbean. Partnerships with local health officials, community engagement, and vaccination facilities in disease-prone areas could accomplish this.

Researching Multivalent Dengue Vaccines

Multivalent dengue vaccinations that protect against all four serotypes offer a huge growth opportunity. Currently, authorized vaccinations defend against individual serotypes or a combination of them. A vaccine that targets all serotypes would be more effective and marketable.

Vaccination Campaigns

Dengue fever awareness and vaccination can boost vaccine demand. This growth opportunity entails large-scale vaccination campaigns, collaborating with healthcare organizations, and using digital channels to educate the public about the vaccine's benefits and availability.

Travel medicine

Travelers to areas where the disease is endemic should be wary of dengue fever. Expanding the dengue vaccine market in travel medicine gives an opportunity for growth. The vaccine can be more widely used by travelers if travel clinics, tour operators, and travel insurance companies work together to promote vaccination as a preventative step.

Vaccine Durability Research:

Dengue vaccine market research and booster doses give a growth opportunity for vaccine makers. Understanding the vaccine's long-term efficacy and the best booster dosage timing could help sustain market growth by assuring product demand and addressing possible protection gaps.

Latest Trends

Dengue Vaccines Drive Market Growth

Millions of people in tropical and subtropical regions are annually infected by the mosquito-borne Dengue Fever virus. Dengue is untreatable, thus vaccination is crucial. The need for dengue virus vaccines has increased globally, which has led to the development of innovative vaccines and vaccine delivery methods.

Tetravalent Dengue Vaccines Protect 100%

The development of tetravalent dengue vaccinations in recent years has advanced dengue fever prevention. In areas with numerous dengue serotypes, these vaccinations protect against all four. Dengvaxia, created by Sanofi Pasteur, is a leading tetravalent dengue vaccine licensed in over 20 countries. Safety and efficacy concerns have led to regulatory limits in various nations.

Innovative Dengue Vaccination Delivery Changes

The development of tetravalent dengue vaccines and the utilization of innovative vaccine delivery methods have received substantial attention. Patches and micro-needles are attractive vaccine delivery methods due to their ease of use, lack of needles, and potential for greater compliance. Vaxxas and NanoPass Technologies are among the companies actively working on the development of such vaccinations.

New Dengue Vaccines for Everyone

The global dengue vaccine market is also shaped by the development of vaccine candidates for different age groups. Dengue vaccinations are licensed for adults and children 9-16 years old. However, newborns and young children, who are most at risk of dengue fever sequelae, are the focus of vaccine development. Companies like Takeda and Butantan Institute are working on vaccine development for these age ranges.

Integration Improves Dengue Vaccines.

Finally, dengue vaccination integration with other immunization programs is expected to be a major market development in the next years. With the development of combination vaccines, you can now prevent numerous diseases with one vaccination. Dengue vaccine integration with other vaccinations can increase immunization program efficiency and coverage, especially in areas with limited healthcare access.

Regional Analysis

The dengue vaccine market in the Asia-Pacific region is dominated by a number of factors that contribute to its significant presence and growth. Numerous countries in the Asia-Pacific region report a substantial number of dengue fever cases each year, resulting in a significant burden of the disease. This frequency increases the need for effective preventative measures, such as vaccines.

India, China, and Indonesia are among the most populous countries in the globe and are located in this region. As a result of the large population, there is a substantial market opportunity for dengue vaccines, as a greater number of individuals may require immunization.

Governments throughout the Asia-Pacific region have instituted vaccination programs in response to the urgency of combating dengue fever. National immunization campaigns and proactive disease control efforts have fostered the growth of the dengue vaccine market.

Numerous Asian countries have actively participated in the development and testing of dengue vaccines. Institutions and pharmaceutical companies in countries such as India, China, and Thailand have made significant strides in vaccine research, which has contributed to the availability of locally produced vaccines.

Rapid economic growth in a number of Asia-Pacific countries has led to an increase in healthcare spending and accessibility. This has resulted in a greater demand for preventative healthcare measures, such as vaccinations, thereby creating a market conducive to dengue vaccines. Actively supporting dengue control initiatives in the region are the World Health Organization (WHO) and the Asian Development Bank (ADB). Collaboration between countries has facilitated the distribution and accessibility of vaccines, thereby accelerating market growth.

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

Sanofi Pasteur has been the market leader in dengue vaccine development. It is believed that its product Dengvaxia, the first dengue vaccine licensed by the U.S. Food and Drug Administration, has the potential to protect against all four serotypes of the dengue virus.

Takeda has also become a significant player in the global dengue vaccine market with its Dengue TAK-003 product. It has been demonstrated to prevent dengue fever caused by serotypes 1, 2, 3, and 4.

Merck Sharp & Dohme (MSD), which has introduced its own dengue vaccine, DengueLink Tetravalent, in several Latin American nations, and Bharat Biotech, which has developed India's first-ever dengue vaccine, Dengvaxia, are also significant players.

Overall, the global dengue vaccine market is extremely competitive, with numerous players vying for a larger market share. However, given the global prevalence of dengue fever, this industry has enormous development and expansion potential.

Top Key Players in Dengue Vaccine Market

• Sanofi Pasteur
• Takeda Pharmaceutical Company
• Biological E Limited
• Panacea Biotec
• Serum Institute of India Pvt. Ltd
• GeneOne Life Science
• Medigen Vaccine Biologics
• Panacea Biotec
• Butantan Institute
• Sun Pharmaceutical Industries Ltd
• Other Key Players

Recent Development

• In 2023, Advances in vaccine delivery systems  To improve the efficacy and convenience of dengue vaccines, researchers have recently focused on devising innovative vaccine delivery systems.
• In 2022, mRNA-based dengue vaccine advancements in 2022  scientists made progress on mRNA-based dengue vaccines.
• In 2021, encouraging results for vaccine candidates TV003/TV005 National Institutes of Health (NIH) researchers reported promising results from Phase 2 clinical trials of TV003 and TV005 dengue vaccine candidates 2021.
• In 2020, Phase 3 clinical trials were concluded, showing efficacy against all four serotypes of dengue virus. These encouraging results inspired optimism for a novel vaccine option.
• In 2020, Takeda Pharmaceutical Company, in collaboration with the Takeda Vaccines Division, continued the development of its dengue vaccine candidate, TAK-003.
• In 2019, Dengvaxia's approval 2019 and ongoing research the World Health Organization (WHO) approved the Dengvaxia Dengue Vaccine for the first time.

Report Scope: